Search
Gyre Therapeutics Inc
GYREAdd to Watchlist
7.340USD
+0.820+12.58%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
670.67MMarket Cap
LossP/E TTM
More Details of Gyre Therapeutics Inc Company
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Gyre Therapeutics Inc Info
Ticker SymbolGYRE
Company nameGyre Therapeutics Inc
IPO dateApr 12, 2006
CEOZhang (Ping)
Number of employees574
Security typeOrdinary Share
Fiscal year-endApr 12
Address12770 High Bluff Drive, Suite 150
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18585677770
Websitehttps://www.gyretx.com/
Ticker SymbolGYRE
IPO dateApr 12, 2006
CEOZhang (Ping)
Company Executives of Gyre Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.81M
--
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
15.00K
--
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board, Interim Chief Executive Officer
Executive Chairman of the Board, Interim Chief Executive Officer
--
--
Dr. Dan Weng
Dr. Dan Weng
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.81M
--
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
15.00K
--
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Gyre Therapeutics Inc?
The top five shareholders of Gyre Therapeutics Inc are: Mr. Songjiang Ma
How many institutions hold shares of Gyre Therapeutics Inc (GYRE)?
As of 2026Q1, 123 institutions hold shares of Gyre Therapeutics Inc, with a combined market value of approximately 4.60M, accounting for 4.74% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1255247.00.
What is the biggest source of revenue for Gyre Therapeutics Inc?
In 2026Q1, the ETUARY business generated the highest revenue for Gyre Therapeutics Inc, amounting to 27.69M and accounting for 90.61% of total revenue.